抑制间变性淋巴瘤激酶可减轻缺血性脑卒中损伤
该研究在小鼠短暂性大脑中动脉闭塞模型中,于卒中后给予ALK抑制剂阿来替尼,发现其可减少活性氧蓄积、脂质过氧化和氧化DNA,抑制血管NLRP3炎症小体通路,减轻血脑屏障损伤和脑梗死体积,并改善神经功能。病毒过表达ALOX15可消除阿来替尼的保护作用,提示其保护效应可能涉及ALOX15。
要点
- 小鼠脑缺血后神经血管单元中ALK表达明显升高。
- 阿来替尼可减轻缺血后氧化应激、血管炎症和血脑屏障损伤。
- 过表达ALOX15可消除阿来替尼的抗氧化应激和神经保护作用。
核心结论
- 阿来替尼通过调控缺血信号级联反应减轻卒中损伤,ALK可能成为缺血性脑卒中的新治疗靶点。
研究设计与样本
- 研究采用小鼠短暂性右侧大脑中动脉线栓闭塞模型,卒中后给予ALK抑制剂阿来替尼,并通过腺病毒注射过表达ALOX15。
主要发现
- 脑缺血后神经血管单元中ALK表达明显升高。
- 阿来替尼减少活性氧蓄积、脂质过氧化和氧化DNA,增加血管抗氧化酶水平,灭活血管NLRP3炎症小体通路,并降低血管ICAM-1和MCP-1水平。
- 阿来替尼减轻脑血管完整性丧失和血脑屏障损伤,减少脑梗死体积并改善神经功能缺损。
- 阿来替尼降低卒中诱导的ALOX15表达,而病毒介导的ALOX15过表达消除了阿来替尼对氧化应激和血管炎症的抑制、血脑屏障保护及神经保护作用。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ischemic stroke is often accompanied by oxidative stress and inflammatory response, both of which work synergistically to exacerbate the disruption of the blood-brain barrier and ischemic brain injury. ALK (anaplastic lymphoma kinase), a cancer-associated receptor tyrosine kinase, was found to play a role in oxidative stress and inflammation. In this study, we investigated the role of ALK inhibition in a murine model of ischemic stroke. METHODS: Focal cerebral ischemia was induced by temporary occlusion of the right middle cerebral artery in mice with a filament. The ALK inhibitor alectinib was administered following the stroke. ALOX15 (arachidonic acid 15-lipoxygenase) was overexpressed by adenovirus injection. The immunohistochemistry, Western blot, oxidative stress, inflammation, blood-brain barrier leakage, infarct volume, and functional outcomes were determined. RESULTS: We found that the expression of ALK was markedly increased in the neurovascular unit after cerebral ischemia. Treatment with the ALK inhibitor alectinib reduced the accumulation of reactive oxygen species, lipid peroxidation, and oxidative DNA, increased the vascular levels of antioxidant enzymes, inactivated the vascular NLRP3 (nucleotide-binding oligomerization domain-like receptor protein 3) inflammasome pathway, and reduced vascular inflammation (ICAM-1 [intercellular adhesion molecule-1] and MCP-1 [monocyte chemoattractant protein-1]) after ischemia. Moreover, alectinib reduced the loss of cerebrovascular integrity and blood-brain barrier damage, consequently decreasing brain infarction and neurological deficits. Furthermore, alectinib reduced stroke-evoked ALOX15 expression, whereas virus-mediated overexpression of ALOX15 abolished alectinib-dependent inhibition of oxidative stress and vascular inflammation, blood-brain barrier protection, and neuroprotection, suggesting the protective effects of alectinib for stroke may involve ALOX15. CONCLUSIONS: Our findings demonstrated that alectinib protects from stroke by regulating ischemic signaling cascades and suggest that ALK may be a novel therapeutic target for ischemic stroke.
引用
- Hu Y, Chang L, Zhu Y, et al. Inhibition of Anaplastic Lymphoma Kinase Protects From Ischemic Stroke. Stroke. 2024. PMID: 38445502. doi:10.1161/STROKEAHA.123.045991
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。